TY - JOUR
AB - Inpharma 1559 - 14 Oct 2006 NICE recommends rituximab for follicular lymphoma . . . The UK NICE has issued guidance to the NHS in England and Wales recommending rituximab in combination with cyclophosphamide, vincristine and prednisolone as an option for the first-line treatment of patients with symptomatic stage III and IV follicular lymphoma. According to Implementation Systems Director at NICE and Executive Lead for the appraisal, Dr Gillian Leng, NICE previously recommended rituximab in 2002 as last-line treatment of stage III or IV follicular lymphoma, and extending the use of rituximab to cover first-line treatment will improve the options available to patients with this form of cancer. . . . and docetaxel for early breast cancer In a separate guidance issued to the NHS, NICE has recommended docetaxel, given concurrently with cyclophosphamide and doxorubicin, as a treatment option for women with early node-positive breast However, the guidance states cancer following surgery. that paclitaxel is not recommended for the treatment of such women. According to Deputy Chief Executive at NICE and Executive Lead for this appraisal, Dr Andrea Sutcliffe, this guidance will give "the best care to patients and use NHS resources most effectively." 1. NICE. NICE recommends rituximab 
TI - NICE recommends rituximab for follicular lymphoma . . .
JF - Inpharma Weekly
DO - 10.2165/00128413-200615590-00003
DA - 2013-02-09
UR - https://www.deepdyve.com/lp/springer-journals/nice-recommends-rituximab-for-follicular-lymphoma-1MIwM8oDtZ
SP - 2
EP - 2
VL - 1559
IS - 1
DP - DeepDyve
ER -